Objectives: IFN-based therapy against hepatitis C recurrence after liver transplantation (LT) has poor effectiveness and tolerability. In HIV/HCV-coinfected liver transplant recipients, the results are even poorer. Here, we report our experience using direct antiviral agents (DAAs) in 11 consecutive coinfected patients within the LT setting.
Introduction
Since the introduction of combined ART (cART) to treat HIV, hepatitis C virus (HCV)-related liver disease has become the main cause of death in HIV/HCV-coinfected patients and therefore liver transplantation (LT) has been increasingly indicated in these patients. However, patient and graft survival after LT is lower in coinfected patients compared with HCV monoinfected patients. 1 -3 The main reason for the lower post-LT survival in coinfected patients is a more aggressive course of hepatitis C recurrence, with a more rapid progression of fibrosis and a higher incidence of fibrosing cholestatic hepatitis (FCH). 4 After LT, successful antiviral therapy against hepatitis C recurrence has been associated with an improvement in clinical and histological outcomes, but the effectiveness of IFN-based regimens in these patients is low ( 30%). 5 In HIV/HCV-coinfected LT patients, the results are even poorer. 6, 7 Castells et al. 6 and Terrault et al. 7 observed a sustained virological response (SVR) rate of 21% and 14%, respectively, in coinfected recipients treated with pegylated IFN and ribavirin. Among the possible explanations for the inferior results in coinfected patients are the high rates of premature discontinuation of therapy due to intolerance and/or adverse events (AEs), the higher severity of liver disease at treatment start or host factors related to HIV infection. 8 The addition of a PI significantly increased SVR rates in liver transplant recipients, but it also increased the toxicity and difficulty in treatment administration due to the presence of drug-drug interactions (DDIs). 9 -11 In HIV/HCV-coinfected recipients, the experience with triple therapy was limited. Antonini et al. 4 reported the results of seven LT patients who received triple therapy with telaprevir (n ¼ 5) or boceprevir (n ¼ 2). Only three patients achieved SVR and six discontinued therapy owing to toxicity.
In patients with advanced liver disease, IFN-based therapies are contraindicated. It has been shown that decompensated cirrhotics (Child -Pugh B or C) awaiting LT who received IFN present a significantly higher rate of bacterial infections and worsening liver function compared with patients with compensated cirrhosis. 12 Moreover, triple therapy with telaprevir or boceprevir administered to cirrhotic patients (especially those with low albumin and low platelets) was associated with increased risk of infection, clinical decompensation and death. 13 The development of direct antiviral agents (DAAs) has allowed the treatment of patients with advanced liver disease including patients awaiting LT, with high rates of viral eradication and in some cases improvement of liver function. 14 -18 In addition, recently published studies have shown SVR rates ,90% in LT recipients with severe hepatitis C recurrence including patients with clinically compensated cirrhosis. 17 -22 In these studies, the tolerance to therapy was excellent. Moreover, studies in non-transplanted patients suggest that HIV does not negatively affect SVR rates in coinfected patients. 23 -27 However, despite the growing amount of information, there are no clinical trials on the use of the newest DAAs in HIV/HCV-coinfected patients in the LT setting. To our knowledge, the only data available at the time of writing consist of two reports. Grant et al. 28 obtained an 87% SVR rate in eight coinfected LT patients with mild hepatitis C recurrence treated with sofosbuvir-based regimens. Similarly, Campos-Varela et al. 29 achieved SVR in two LT HIV-infected patients with HCV-decompensated cirrhosis treated with sofosbuvir, simeprevir and ribavirin. The aim of this article is to report our initial experience with the use of IFN-free regimens in HIV/HCV-coinfected patients with advanced liver disease within the LT setting.
Patients and methods

Patients
Eleven consecutive HIV/HCV-coinfected patients, who received antiviral therapy with an IFN-free regimen to treat HCV, were included.
Four patients with compensated cirrhosis received antiviral therapy while awaiting LT in order to prevent infection of the graft. Hepatocellular carcinoma (HCC) was the indication for LT in these patients. Seven patients received therapy after LT [median time of 61 months (range 11 -120 months)] because of severe hepatitis C recurrence defined by one of the following criteria: fibrosis F3 or F4 in a liver biopsy (assessed by METAVIR), hepatic venous pressure gradient ≥6 mmHg or clinical, analytical or radiological signs of cirrhosis.
Hepatitis C antiviral therapy
The treatment regimen was decided by the treating physician based on published guidelines, potential for DDIs and information available at the time of treatment indication. DAAs were administered according to the recommendations of the specific insert packages during 12 or 24 weeks with or without ribavirin.
Ribavirin was employed in all patients with haemoglobin levels ≥10 g/dL and glomerular filtration rate ≥30 mL/min. In patients with fibrosis F3 or compensated cirrhosis, starting ribavirin dose was weight based (1000 -1200 mg/day) and in patients with decompensated cirrhosis, ribavirin was started at 600 mg/day.
ART
All patients were on cART: seven patients were receiving a combination of two NRTIs plus an integrase strand transfer inhibitor (INSTI); two patients were receiving a combination of two NRTIs, an INSTI and a ritonavir-boosted PI (PI/r); one patient was receiving a combination of two NRTIs, an INSTI, a PI/r and an NNRTI; and one patient was receiving two NRTIs, an INSTI and an NNRTI.
Monitoring
Liver chemistries, haematological data, renal function, immunosuppression trough levels and HCV-RNA levels were monitored at baseline, every 4 weeks during antiviral therapy, at the end of therapy (EOT) and at weeks 4 and 12 after treatment discontinuation. Rapid virological response (RVR) was defined as the presence of undetectable HCV-RNA at week 4 of antiviral therapy. SVR (SVR12) was defined as the presence of undetectable HCV-RNA 12 weeks after discontinuing antiviral therapy. HIV viral load and CD4+ T cell count were analysed at baseline and after EOT.
Tolerability
The tolerability of antiviral therapy was evaluated at each visit (with a 4 week minimum frequency) in order to detect the presence of any AEs including anaemia (haemoglobin ,10 g/dL), photosensitivity, rash, transaminase increase (.2× baseline levels), gastrointestinal abnormalities or any other AEs described by the patients. In patients who presented anaemia or a decrease ≥2 g/dL in haemoglobin levels within 4 weeks, ribavirin dose was decreased by 200 mg every 2 weeks until stabilization.
Results
Patients awaiting LT
Four HIV/HCV-coinfected patients with compensated cirrhosis and HCC on the waiting list for LT received antiviral therapy with an IFN-free regimen. The characteristics of these patients are shown in Table 1 . Sofosbuvir/ledipasvir/ribavirin was administered in two patients while sofosbuvir/ribavirin and sofosbuvir/daclatasvir were administered in one patient each. Median model for end-stage liver disease (MELD) and Child-Pugh scores were 7 and 5, respectively. Two patients were infected with genotype 3, one with genotype 1a and one with genotype 4. Three patients were non-responders to a previous course of an IFN-based therapy. Median duration of therapy before LT was 19 weeks (range 12-24 weeks).
RVR and EOT were achieved in three and four patients, respectively. SVR was achieved in all four patients (100% effectiveness). Three patients have already received LT. In two of these three patients, HCV-RNA was undetectable at the time of LT and has remained undetectable post-operatively .12 weeks after the transplant. In the third patient, HCV-RNA was positive at the time of LT (after 8 weeks of therapy) and antiviral treatment was continued after transplantation (as soon as oral intake was resumed) until completing 12 weeks of therapy, with achievement of SVR. The fourth patient, also with SVR, is still awaiting LT. As expected, antiviral therapy was associated with a significant decrease in transaminase levels. However, there was no impact of viral eradication on liver function tests because these patients had compensated cirrhosis with normal or mildly altered liver function ( Figure S1 , available as Supplementary data at JAC Online). Tolerance to therapy was excellent and no patient had any AE.
Liver transplant recipients
Seven liver transplant recipients with severe hepatitis C recurrence and HCV/HIV coinfection received antiviral therapy with DAAs (Table 2) . Sofosbuvir/ledipasvir/ribavirin was administered in four Londoñ o et al.
patients and sofosbuvir/daclatasvir/ribavirin, sofosbuvir/simeprevir/ribavirin and sofosbuvir/daclatasvir in one patient each. All patients were males, with a median age of 51 years (range 42 -54 years) and infected with genotype 1a (n¼ 4) or 4 (n ¼ 3). The indication for antiviral therapy was decompensated cirrhosis in four patients [ascites (n¼ 4), hepatic encephalopathy (n¼ 1) and spontaneous bacterial peritonitis (n¼ 1)], advanced fibrosis stage (F3) in two patients, and FCH in one patient. Four patients had not responded to a previous course of therapy with pegylated IFN and ribavirin administered after transplantation. Median MELD and Child -Pugh scores were 9 and 6, respectively. All patients were on cARTand six had undetectable HIV-RNA. The remaining patient had HIV-RNA levels of 231 copies/mL despite the combination of five drugs (Patient 8), although HIV-RNA became undetectable (,37 copies/mL) after HCV eradication. No changes in cART were required during therapy against HCV and the CD4+ T cell count remained stable. Baseline immunosuppression is shown in Table 2 . The dose of tacrolimus did not require modification during therapy, but cyclosporine was adjusted in the two patients who were receiving this drug (discontinued in one patient due to renal failure and increased in one patient due to a decline in cyclosporine trough levels during therapy).
Five patients (71%) had RVR and all seven patients achieved EOT response and SVR12 (100% effectiveness). At the time of SVR12, viral eradication was associated with an improvement in transaminase levels and liver function tests including total bilirubin, albumin and international normalized ratio ( Figure S2 ). Although the differences were not statistically significant (probably because of the small number of patients), they were considered clinically relevant. The control of ascites improved in all four patients who presented this sign at baseline (one patient ceased needing paracentesis and three patients decreased diuretic dose at the time of SVR12). The patient with previous history of hepatic encephalopathy did not present new episodes. At the time of last follow-up [median time of 11.5 months (range: 9.7 -18.7) since the beginning of antiviral therapy] there was a statistically significant improvement in Child -Pugh and MELD scores as compared with baseline and EOT, respectively. Antiviral therapy was well tolerated. AEs were mild and reported in four patients: hyperbilirubinaemia (maximum level of 2.5 mg/dL), anaemia (observed at week 8 of therapy in one patient receiving ribavirin with minimum haemoglobin level of 10 g/dL that did not lead to ribavirin dose reduction or discontinuation), fatigue and renal failure secondary to calcineurin inhibitor toxicity in one patient each.
Discussion
We report our initial experience with IFN-free regimens in HIV/ HCV-coinfected patients with advanced liver disease within an LT setting. Antiviral therapy yields excellent results in terms of effectiveness and tolerability, both before and after LT. The information reported in these variables corresponds to laboratory data at treatment baseline. (28) 445 (28) 464 (14) 147 (10) 311 (28) 217 (24) Currently, there is only one clinical trial evaluating the use of sofosbuvir/ribavirin in non-HIV, compensated cirrhotic patients with HCC awaiting LT.
14 In this trial, 70% of the patients achieved post-transplant SVR with no significant AEs. The major predictor of SVR was the presence of undetectable HCV-RNA for ≥30 days before transplant. In our experience, the results of antiviral therapy with DAAs in our four coinfected patients with compensated cirrhosis and HCC awaiting LT are excellent. This is similar to observations in HIV/HCV-coinfected patients with chronic hepatitis C, in which SVR rates are high and very similar to those reported in monoinfected patients. 23 -27 Two of the three patients who had reached LT had undetectable HCV-RNA at the time of transplant for .30 days (90 and 170 days, respectively) and none had HCV infection recurrence after transplantation. More data are needed to determine whether ≥30 days of undetectable HCV-RNA before LT is still necessary when more potent combinations of DAAs are used. Interestingly, the patient with positive HCV-RNA at LT completed the therapy after transplantation with an excellent tolerability and achieved SVR. A similar, successful case has been reported by Donato et al., 30 suggesting that, although it is probably not the optimal strategy, selected liver transplant recipients might complete or start antiviral therapy within the very early post-operative period with good results in terms of efficacy and tolerability.
Besides preventing hepatitis C recurrence after LT, viral eradication in patients with advanced liver disease awaiting LT is associated with an improvement in liver function that, at least in some cases, could lead to delisting. Data from three real-life cohorts analysing the impact of antiviral therapy in patients awaiting LT were recently reported. 31 -33 Coilly et al. 33 showed that 36% of treated patients with decompensated cirrhosis experienced clinical improvement and 16% were delisted. Similar results were observed by Belli et al. 31 and Pascasio et al., 32 where 20% of the patients were delisted after effective antiviral therapy. In HIV/ HCV-coinfected patients, Llaneras et al. 34 reported the case of one patient delisted after viral eradication with sofosbuvir and daclatasvir. In our series, there was no significant clinical or analytical improvement after viral eradication, because these four patients treated on the waiting list for LT already had compensated cirrhosis with mild alteration in liver function. In addition, delisting was not possible because the indication for LT was the presence of HCC with no other curative treatment options.
On the other hand, the main concern of treating hepatitis C before LT is that SVR might lead to some improvement in MELD score and symptoms of clinical decompensation but not enough to eliminate the need for a transplant and making the access to transplantation less likely (this is commonly referred as 'MELD purgatory'). Currently, there are no guidelines to decide who will or will not benefit from treating HCV before transplantation and the recommendation for antiviral therapy to these patients should be evaluated individually depending on baseline liver function and the specific aims of viral eradication (prevention of hepatitis C recurrence, prevention of waiting list mortality or delisting). 35 There are no large clinical trials evaluating the efficacy and safety of DAAs in HIV/HCV-coinfected liver transplant recipients. In HIV-negative patients, data from clinical trials and real-life cohorts have shown excellent results with SVR up to 97% in patients with mild/moderate fibrosis or compensated cirrhosis. 16,20 -22 Recently, Grant et al. 28 reported their experience with sofosbuvir-based therapy administered for 12 weeks in eight LT recipients with mild hepatitis C recurrence (fibrosis F0 -F2) and HIV coinfection. Seven patients completed the therapy and achieved SVR (88%). In our series composed of patients with severe hepatitis C recurrence (most with decompensated cirrhosis or FCH), the results were excellent: 100% SVR and good tolerance. Campos-Varela et al. 29 also described successful therapy with sofosbuvir/simeprevir in two HCV/HIV-coinfected patients with severe hepatitis C recurrence after transplantation. In contrast, the outcomes reported at the time of writing in HIV-uninfected LT patients with severe hepatitis C recurrence and significant liver dysfunction have been poorer. Results from the sofosbuvir compassionate use study in 102 patients with severe hepatitis C recurrence showed lower SVR rates in liver transplant recipients who received antiviral therapy when cirrhosis was established (late recurrence) compared with patients with early severe hepatitis C recurrence (severe acute hepatitis or FCH, 43% versus 73%, respectively). 36 In another study, the combination of sofosbuvir/ ledipasvir/ribavirin administered to HIV-uninfected liver transplant recipients with decompensated cirrhosis obtained SVR rates of 60% and 67% (Child-Pugh B and C, respectively). 16 The small sample size of our cohort prevents us from drawing any conclusions about the better effectiveness in coinfected LT patients compared with monoinfected liver transplant recipients and more data are needed to confirm these results.
Of note, and similar to what has been observed in clinical trials or compassionate use studies in non-HIV LT patients, 16 ,37 viral eradication in our HCV/HIV-coinfected patients was associated with a significant improvement in liver function tests and clinical status. However, since our liver transplant recipients had severe liver disease, mostly cirrhosis, the long-term patient and graft outcome is uncertain. Therefore, despite our excellent results with antiviral treatment administered late after transplantation, an early therapy, before severe fibrosis is established, appears to be more adequate in order to obtain a better long-term outcome.
One of the major issues with the use of DAAs in coinfected liver transplant recipients is the potential for DDI with cART and/or immunosuppressive therapy. 38, 39 Simeprevir should not be used with anti-HIV NNRTIs and PIs. In addition, the use of simeprevir with cyclosporine results in significantly increased simeprevir levels (due to hepatic transporter inhibition) and the coadministration of these two drugs is not recommended. In this article, only one patient received simeprevir, but he did not require treatment adjustments (Patient 5). Daclatasvir can be coadministered with cART and immunosuppressive therapy, but it is recommended to reduce the dose in patients receiving regimens containing ritonavir. One of our patients (Patient 8) started antiviral therapy with low-dose daclatasvir (30 mg/day) due to the potential DDI with darunavir/ritonavir. This DDI was not subsequently confirmed and the daclatasvir dose was increased up to 60 mg/ day at week 12 of treatment. Sofosbuvir/ledipasvir can be coadministered with antiretrovirals and immunosuppressants. Increases in tenofovir levels may be observed when used with ledipasvir. PI/r used for HIV have also been shown to increase tenofovir levels. Therefore, when using a PI/r with tenofovir and sofosbuvir/ledipasvir, there may be an increased risk of tenofovirinduced renal toxicity. The use of alternative HCV therapy or changes in HIV ART to a tenofovir-free regimen should be considered and where this is not possible, close monitoring for tenofovirassociated nephrotoxicity is mandatory. 40 In summary, our data suggest that IFN-free regimens are very efficacious and well tolerated in HIV/HCV-coinfected patients with DAAs in HIV/HCV coinfection and liver transplant 3199 JAC advanced liver disease while on the waiting list for LT or after LT. Similar to observations in HCV monoinfected recipients, viral eradication is associated with an improvement in clinical and biochemical liver status. More data are needed to confirm these results and to establish the best treatment option and treatment duration in this subpopulation. A longer follow-up of these patients will determine whether viral eradication will improve patient and graft survival.
